MPN

Recent studies found that for certain patients with CML, it is possible to safely reduce or stop TKI treatment.

Eight individuals were honored for their dedication to MPN at the 2016 MPN Heroes™ celebration.

The NCCN updated their guidelines on treatment for myeloproliferative neoplasms (MPNs), outlining diagnosis, treatment and care strategies.

Checkpoint inhibitors such as Opdivo and Yervoy are showing promise in treating MDS and AML.

Srdan Verstovsek, M.D., Ph.D. talks to CURE about recent advances in treating MPNs.

A recent study showed that patients with MPNs treated with Jakafi off a clinical trial still benefited from the drug.

Pacritinib decreased spleen size, but did not improve total symptom scores in a group of patients with myelofibrosis.

The MPN Research Foundation wants to empower patients through initiatives such as their MPN patient registry.

Barbara Van Husen, president of the MPN Research Foundation, discusses how after the discovery of the JAK2 mutation in 2005, MPN research and treatment advances proliferated. Now, Van Husen says, it is one of the most active areas of hematological research

CURE recently interviewed Naveen Pemmaraju to discuss the unique aspects of the MPN community, the pitfalls of social media and the importance of patients and physicians interacting.

Jennifer Arnold, our MPN Heroes guest speaker, a physician and star of TLC’s reality TV show “The Little Couple,” discusses the importance of doctors and caregivers taking a moment to listen to patients and see how they are feeling.

Many patients with myeloproliferative neoplasms often are burdened with sexual dysfunction, a study says. However, the issue is not often discussed between patients and their doctors.

Susan Melvin Hill, patient advocate, tells her MPN story and discusses how she helps patients with myeloproliferative neoplasms (MPNs) in Idaho.

Jason R. Gotlib discusses JAK inhibitors for the treatment of patients with myelofibrosis.

Imagine a beautiful expanse in the Southwest, a desert landscape stretching across sandswept miles until it reaches mountains that rise into the starry night sky.

The FDA has placed a full clinical hold on pacritinib following reports of patient deaths related to intracranial hemorrhage, cardiac failure and cardiac arrest in the phase 3 PERSIST-2 trial.

An essay honoring Emily A. Knight, RN, OCN [Mayo Clinic Cancer Center in Scottsdale, Arizona.

Jason R. Gotlib discusses the research being done at his institution. Gotlib is a 2015 MPN Hero in the category of Commitment to the Individual and is also an international leader in MPN research.

David T. Boule discusses the challenges and rewards of patient advocacy.

Rebecca N. Claassen discusses the importance of educating nurses about myeloproliferative neoplasms (MPNs).

Susan Melvin Hill, patient advocate, discusses how she meets with and helps patients with myeloproliferative neoplasms (MPNs) in Idaho.

Barbara Van Husen, president, MPN Research Foundation, discusses research into myeloproliferative neoplasms.

David Allen Denny, an administrator of the Myelofibrosis Private Support Group, tells the story of his diagnosis.

Jennifer Arnold, a physician and a star of TLC's reality TV show "The Little Couple," pays tribute to our MPN Heroes.

At CURE's Third Annual MPN Heroes celebration, "grace" was the word of the night.

Richard Silver, an oncologist focused on rare blood diseases called myeloproliferative neoplasms was named an MPN Hero for Commitment to the Broader MPN Community for 2014.

David Alexander was selected as an MPN Hero at this year's MPN Heroes event. The MPN Heroes event honors clinicians, caregivers, and advocates who have made significant contributions in the field of myeloproliferative neoplasms (MPNs).

Antje Hjerpe was nominated as an MPN Hero for her long-term dedication, stewardship and volunteer service to the organization.

The FDA has approved Jakafi (ruxolitinib) as a treatment for patients with polycythemia vera who are resistant or intolerant to hydroxyurea, based on findings from the phase 3 RESPONSE trial.